ENTPD1 and colonic neoplasm: reported that B66, an anti-CD39 antibody, reversed the resistance of colon cancer to PD-1 mAbs and the release of IL-18/IL-1β to inhibit colon cancer growth in mice by activating neutrophilic alkaline phosphatase 3 inflammatory vesicles, thereby elucidating another anti-tumor mechanism of anti-CD39 antibodies (182).